Description

Translational Neuroimaging: Tools for CNS Drug Discovery, Development and Treatment combines the experience of academic, clinical and industrial neuroimagers in a unique collaborative approach to provide an integrated perspective of the use of small animal and human brain imaging in developing and validating translational models and biomarkers for the study and treatment of neuropsychiatric disorders. Translational Neuroimaging: Tools for CNS Drug Discovery, Development and Treatment examines the translational role of neuroimaging in model development from preclinical animal models, to human experimental medicine, and finally to clinical studies. The focus of this book is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This book covers methodical issues in human and animal neuroimaging translational research as well as detailed applied examples of the use of neuroimaging in neuropsychiatric disorders and the development of drugs for their treatment. Offering an accompanying website with illustrations and text available for further knowledge and presentations, Translational Neuroimaging: Tools for CNS Drug Discovery, Development and Treatment appeals to non-clinical and clinical neuroscientists working in and studying neuropsychiatric disorders and their treatment as well as providing the novice researcher or researcher outside of his/her expertise the opportunity to understand the background of translational research and the use of imaging in this field.

Key Features

  • Provides a background to translational research and the use of brain imaging in neuropsychiatric disorders
  • Critical discussion of the potential and limitations of neuroimaging as a translational tool for identifying and validating biomarkers
  • Identifies cross species neurosystems and common endpoints necessary to help accelerate CNS drug discovery and development for the treatment of neuropsychiatric disorders
  • Features an accompanying website with additional images and text

Readership

Primary Market: Researchers in the biopharmaceutical industry and academic who actively work on CNS drug treatment studies, often found in molecular biology, pharmacology, neuroscience, and psychiatry departments drug delivery groups, as well as, researchers using animal models to study drug development and therapeutics.

Secondary Market: Graduate students, postdocs and professors at medical schools studying translational medicine.

Table of Contents

Dedication

Preface

1.0 Introduction

2.0 Fundamentals of Neuroimaging

3.0 Translational Neuroimaging

Contributors

Acknowledgments

Abbreviation List

Chapter 1. Neuroimaging Modalities: Description, Comparisons, Strengths, and Weaknesses

1.0 Introduction

2.0 Radiotracer Techniques

3.0 Electrophysiological Techniques

4.0 Magnetic Resonance Techniques

5.0 Advantages, Disadvantages, and Practical Considerations

References

Chapter 2. Magnetic Resonance Imaging as a Tool for Modeling Drug Treatment of CNS Disorders: Strengths and Weaknesses

1.0 Introduction

2.0 MRI

3.0 MRS

4.0 Bold fMRI

5.0 Arterial Spin Labeling of Blood Flow

6.0 Conclusions

Acknowledgments

References

Chapter 3. Small Animal Imaging as a Tool for Modeling CNS Disorders: Strengths and Weaknesses

1.0 Introduction

2.0 Setting Up and Imaging Awake Animals

3.0 Typical Study Designs

4.0 Summary

Acknowledgments

References

Chapter 4. Structural Magnetic Resonance Imaging as a Biomarker for the Diagnosis, Progression, and Treatment of Alzheimer Disease

1.0 Introduction

2.0 Functional Readout of Volumetric MRI

3.0 Correlation of Structural MRI with the Neuropathology of Alzheimer Disease

4.0 Prediction of Clinical Progression to Dementia

5.0 Structural MRI in Therapeutic Clinical Trials

6.0 Use of Structural MRI in a Regulatory Setting

7.0 Conclusions

References

Chapter 5. Positron Emission Tomography in Alzheimer Disease: Diagnosis and Use as Biomarker Endpoints

1.0 Introduction

2.0 Historical Perspective

3.0 Pet as a Biomarker for Alzheimer Disease

4.0 FDG-PET

5.0 Amyloid Pet

6.0 Clinical Relevance of Amyloid Pet

7.0 Future Directions

Details

No. of pages:
464
Language:
English
Copyright:
© 2012
Published:
Imprint:
Academic Press
Print ISBN:
9780123869456
Electronic ISBN:
9780123869975

About the author

Robert McArthur

Dr. McArthur began his professional career investigating the role of serotonin on feeding behaviour at the Clarke Institute of Psychiatry in Toronto, Canada. This interest led him to complete a PhD in the psychopharmacology of feeding behaviour and macronutrient selection with John Blundell at the University of Leeds, Leeds, UK. In 1981 he joined Beecham Pharmaceuticals to work on adrenergic involvement in energy expenditure and obesity. In 1983 Dr McArthur began working on M1 functional agonists for the treatment of Alzheimer disease and was responsible for demonstrating the initial procognitive effects of Sabcomeline. Following the merger of Beecham with SmithKline French, Dr McArthur was appointed Business Development Executive at I.T.E.M-Labo, Paris working with Roger Porsolt in behavioural pharmacology contract research. In 1992, Robert was appointed Head of Behavioral Pharmacology at Farmitalia Carlo Erba, later Pharmacia in Milan. His lab was responsible for the preclinical behavioural pharmacology of Sabcomeline (Alzheimer’s and schizophrenia); Safinamide (epilepsy and Parkinson’s); Reboxetine (depression); Cabergoline (Parkinson’s); Nicergoline (Mild Cognitive Impairment); and Amperozide (alcoholism). He is listed as an inventor in 19 issued patents and applications of which he is the principal inventor in 3. In 1998, Robert transferred to the Pharmacia and Upjohn Company in Kalamazoo, Michigan where as senior behavioural pharmacologist responsible, he worked on mutant mouse characterizations, the establishment of a primate unit assessing cognitive changes in monkeys (CANTAB), and development of anxiety models in marmosets. Soon after the merger of Pharmacia and Upjohn with Monsanto-Searle, Robert returned to Europe where in 2001 he founded the consulting company, McArthur and Associates GmbH in Basel. Robert has since worked on a series of projects for both large Pharma as well as biotechs, including further primate work in Parkinson’s, develop

Reviews

"This book examines how neuroimaging can play a role in translational research by developing preclinical models and ultimately clinical studies for drug discovery."--Doody.com, October 17, 2013
"Researchers in imaging technology, neurology, and mental health sciences introduce fundamental concepts of neuroimaging, the various modalities being used, how it is being used to study central nervous system (CNS) disorders, and specifically how it is being used to discover and develop drugs for such disorders."--Reference & Research Book News, October 2013